Longitudinal validation of periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH OA Biomarkers Consortium.

Published

Journal Article

OBJECTIVE: To perform a longitudinal validation study of imaging bone biomarkers of knee osteoarthritis (OA) progression. METHODS: We undertook a nested case-control study within the Osteoarthritis Initiative in knees (one knee per subject) with a Kellgren and Lawrence grade of 1-3. Cases were defined as knees having the combination of medial tibiofemoral radiographic progression and pain progression at the 24-month, 36-month or 48-month follow-up compared with baseline. Controls (n=406) were eligible knees that did not meet both endpoint criteria and included 200 with neither radiographic nor pain progression, 103 with radiographic progression only and 103 with pain progression only. Bone surfaces in medial and lateral femur, tibia and patella compartments were segmented from MR images using active appearance models. Independent variables of primary interest included change from baseline to 24 months in (1) total area of bone and (2) position on three-dimensional (3D) bone shape vectors that discriminate OA versus non-OA shapes. We assessed the association of bone markers changes over 24 months with progression using logistic regression. RESULTS: 24-month changes in bone area and shape in all compartments were greater in cases than controls, with ORs of being a case per 1 SD increase in bone area ranging from 1.28 to 1.71 across compartments, and per 1 SD greater change in 3D shape vectors ranging from 1.22 to 1.64. Bone markers were associated most strongly with radiographic progression and only weakly with pain progression. CONCLUSIONS: In knees with mild-to-moderate radiographic OA, changes in bone area and shape over 24 months are associated with the combination of radiographic and pain progression over 48 months. This finding of association with longer term clinical outcome underscores their potential for being an efficacy of intervention biomarker in clinical trials.

Full Text

Duke Authors

Cited Authors

  • Hunter, D; Nevitt, M; Lynch, J; Kraus, VB; Katz, JN; Collins, JE; Bowes, M; Guermazi, A; Roemer, FW; Losina, E; FNIH OA Biomarkers Consortium,

Published Date

  • September 2016

Published In

Volume / Issue

  • 75 / 9

Start / End Page

  • 1607 - 1614

PubMed ID

  • 26483253

Pubmed Central ID

  • 26483253

Electronic International Standard Serial Number (EISSN)

  • 1468-2060

Digital Object Identifier (DOI)

  • 10.1136/annrheumdis-2015-207602

Language

  • eng

Conference Location

  • England